SEGMENT REPORTING (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle

The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three and six months ended June 30, 2025 and 2024:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Revenues:
Product revenue, net	$	49.0	$	0.8	$	88.4	$	0.8
Royalties	—		0.1		0.2		0.4
Total revenues	$	49.0	$	0.9	$	88.6	$	1.2
Costs and operating expenses:
Cost of goods sold	1.2		—		2.4		—
Research and development
Research and clinical expenses	19.8		18.5		33.5		36.2
Chemistry, manufacturing, and control expenses	1.9		12.3		3.3		24.0
Selling, general and administrative
Commercial expenses	18.8		18.9		36.5		29.0
Other segment expenses*	19.8		20.5		42.1		37.5
Total operating expenses	$	61.5	$	70.2	$	117.8	$	126.7
Loss from operations	(12.5)		(69.3)		(29.2)		(125.5)
Total interest and other income (expense)	(3.9)		2.0		$	(7.1)	2.7
Net loss	$	16.4	$	67.3	$	(36.2)	$	(122.8)

___________________________

*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.